Arcadia Biosciences (NASDAQ:RKDA) Stock Rating Upgraded by ValuEngine

Arcadia Biosciences (NASDAQ:RKDA) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Thursday, ValuEngine reports.

Several other analysts also recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Arcadia Biosciences in a research report on Monday, August 12th. National Securities boosted their target price on shares of Arcadia Biosciences from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th.

RKDA stock opened at $4.35 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.29 and a quick ratio of 5.09. Arcadia Biosciences has a 12 month low of $1.82 and a 12 month high of $10.40. The firm has a 50 day moving average of $5.97 and a two-hundred day moving average of $5.08.

Arcadia Biosciences (NASDAQ:RKDA) last posted its earnings results on Wednesday, August 14th. The basic materials company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.08). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. Arcadia Biosciences had a negative return on equity of 157.32% and a negative net margin of 388.94%. Research analysts anticipate that Arcadia Biosciences will post -3.56 EPS for the current year.

In other news, Director Kevin Comcowich acquired 5,000 shares of Arcadia Biosciences stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $5.88 per share, for a total transaction of $29,400.00. Following the completion of the purchase, the director now owns 20,000 shares of the company’s stock, valued at $117,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Matthew T. Plavan acquired 8,000 shares of Arcadia Biosciences stock in a transaction dated Wednesday, August 28th. The stock was purchased at an average price of $8.73 per share, with a total value of $69,840.00. The disclosure for this purchase can be found here. Insiders acquired 33,200 shares of company stock valued at $227,886 over the last three months. Insiders own 3.30% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. CVI Holdings LLC acquired a new stake in shares of Arcadia Biosciences in the second quarter worth $414,000. Vanguard Group Inc. lifted its stake in shares of Arcadia Biosciences by 47.1% in the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock worth $359,000 after buying an additional 37,472 shares during the last quarter. Morgan Stanley lifted its stake in shares of Arcadia Biosciences by 162,800.0% in the second quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock worth $250,000 after buying an additional 81,400 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Arcadia Biosciences in the second quarter worth $34,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Arcadia Biosciences in the second quarter worth $32,000. Institutional investors and hedge funds own 6.58% of the company’s stock.

About Arcadia Biosciences

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

Featured Story: What are catch-up contributions?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit